Cargando…
Driving better and safer HER2-specific CARs for cancer therapy
Given the clinical efficacy of chimeric antigen receptor (CAR)-based therapy in hematological malignancies, CAR T-cell therapy for a number of solid tumors has been actively investigated. Human epidermal growth factor receptor 2 (HER2) is a well-established therapeutic target in breast, as well as o...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617544/ https://www.ncbi.nlm.nih.gov/pubmed/28977984 http://dx.doi.org/10.18632/oncotarget.17528 |
_version_ | 1783267012481384448 |
---|---|
author | Liu, Xianqiang Zhang, Nan Shi, Huan |
author_facet | Liu, Xianqiang Zhang, Nan Shi, Huan |
author_sort | Liu, Xianqiang |
collection | PubMed |
description | Given the clinical efficacy of chimeric antigen receptor (CAR)-based therapy in hematological malignancies, CAR T-cell therapy for a number of solid tumors has been actively investigated. Human epidermal growth factor receptor 2 (HER2) is a well-established therapeutic target in breast, as well as other types of cancer. However, HER2 CAR T cells pose a risk of lethal toxicity including cytokine release syndrome from “on-target, off-tumor” recognition of HER2. In this review, we summarize the development of conventional HER2 CAR technology, the alternative selection of CAR hosts, the novel HER2 CAR designs, clinical studies and toxicity. Furthermore, we also discuss the main strategies for improving the safety of HER2 CAR-based cancer therapies. |
format | Online Article Text |
id | pubmed-5617544 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-56175442017-10-03 Driving better and safer HER2-specific CARs for cancer therapy Liu, Xianqiang Zhang, Nan Shi, Huan Oncotarget Review Given the clinical efficacy of chimeric antigen receptor (CAR)-based therapy in hematological malignancies, CAR T-cell therapy for a number of solid tumors has been actively investigated. Human epidermal growth factor receptor 2 (HER2) is a well-established therapeutic target in breast, as well as other types of cancer. However, HER2 CAR T cells pose a risk of lethal toxicity including cytokine release syndrome from “on-target, off-tumor” recognition of HER2. In this review, we summarize the development of conventional HER2 CAR technology, the alternative selection of CAR hosts, the novel HER2 CAR designs, clinical studies and toxicity. Furthermore, we also discuss the main strategies for improving the safety of HER2 CAR-based cancer therapies. Impact Journals LLC 2017-04-29 /pmc/articles/PMC5617544/ /pubmed/28977984 http://dx.doi.org/10.18632/oncotarget.17528 Text en Copyright: © 2017 Liu et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Liu, Xianqiang Zhang, Nan Shi, Huan Driving better and safer HER2-specific CARs for cancer therapy |
title | Driving better and safer HER2-specific CARs for cancer therapy |
title_full | Driving better and safer HER2-specific CARs for cancer therapy |
title_fullStr | Driving better and safer HER2-specific CARs for cancer therapy |
title_full_unstemmed | Driving better and safer HER2-specific CARs for cancer therapy |
title_short | Driving better and safer HER2-specific CARs for cancer therapy |
title_sort | driving better and safer her2-specific cars for cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617544/ https://www.ncbi.nlm.nih.gov/pubmed/28977984 http://dx.doi.org/10.18632/oncotarget.17528 |
work_keys_str_mv | AT liuxianqiang drivingbetterandsaferher2specificcarsforcancertherapy AT zhangnan drivingbetterandsaferher2specificcarsforcancertherapy AT shihuan drivingbetterandsaferher2specificcarsforcancertherapy |